Mer­ck high­lights sub­cu­ta­neous de­mand even as Keytru­da sales soar

Mer­ck said Keytru­da sales jumped 21% to $6.6 bil­lion in the fourth quar­ter of the year, dri­ven by new ap­provals in ear­li­er-stage in­di­ca­tions for breast can­cer and re­nal cell car­ci­no­ma, and more de­mand in metasta­t­ic can­cers.

The com­pa­ny’s crown jew­el made up near­ly half of its rev­enue in the fi­nal three months of the year.

The block­buster scored mul­ti­ple ap­provals last year, in­clud­ing in com­bi­na­tion with Astel­las and Pfiz­er’s Pad­cev for first-line treat­ment of urothe­lial can­cer; with chemora­dio­ther­a­py for a spe­cif­ic late-stage cer­vi­cal can­cer; as a first-line treat­ment for HER2-neg­a­tive gas­tric can­cer; and in com­bi­na­tion with gem­c­itabine and cis­platin for bil­iary tract can­cer.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER